SCHEMBL6205795

SCHEMBL6205795

Cc1ccccc1C1C(C)CCCN1CC(=O)N(Cc1ccccc1F)C1Cc2ccccc2C1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.45
OPRM1 P35372 2/20 0.42
THRB P10828 1/20 0.41
ALDH1A1 P00352 6/20 0.39
POLB P06746 1/20 0.37
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
LMNA P02545 1/20 0.36
DRD4 P21917 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KDM4E B2RXH2 1/20 0.35
TACR1 P25103 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6207404 0.90 C5AR1 (0.47) C5AR1OPRM1THRBALDH1A1POLB
SCHEMBL5136056 0.83 C5AR1 (0.56) C5AR1OPRM1THRBALDH1A1MEN1
SCHEMBL6259390 0.83 C5AR1 (0.56) C5AR1OPRM1THRBALDH1A1MEN1
SCHEMBL6342639 0.83 C5AR1 (0.56) C5AR1OPRM1THRBALDH1A1MEN1
SCHEMBL5134538 0.82 C5AR1 (0.45) C5AR1OPRM1THRBALDH1A1MEN1
SCHEMBL5071438 0.82 C5AR1 (0.45) C5AR1OPRM1THRBALDH1A1MEN1
SCHEMBL6342084 0.82 C5AR1 (0.45) C5AR1OPRM1THRBALDH1A1MEN1
SCHEMBL6341196 0.82 C5AR1 (0.45) C5AR1OPRM1THRBALDH1A1MEN1
SCHEMBL6344626 0.82 C5AR1 (0.45) C5AR1OPRM1THRBALDH1A1MEN1
SCHEMBL6206595 0.81 C5AR1 (0.48) C5AR1OPRM1THRBALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487798-A4 SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS NEUROGEN CORP (US) 2005-07-13 EP claimed
US-6916830-B2 Substituted tetrahydroisoquinolines as C5a receptor modulators NEUROGEN CORPORATION (US) 2005-07-12 US claimed
EP-1487798-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS Neurogen Corporation (US) 2004-12-22 EP claimed
US-20040204446-A1 Nitrogen compounds such as N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(3-methyl-2-o-tolyl-piperidin-1-yl) -acetamide, administered for prophylaxis arthritis, psoriasis, cardiovascular disorders, reperfusion injury or respiratory system disorders NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2004-10-14 US claimed
US-20040006069-A1 Substituted tetrahydroisoquinolines as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2004-01-08 US claimed
WO-2003082828-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2003-10-09 WO claimed
US-6916830-B2 Substituted tetrahydroisoquinolines as C5a receptor modulators NEUROGEN CORPORATION (US) 2005-07-12 US disclosed
US-6777422-B2 FOR TREATING A VARIETY OF INFLAMMATORY AND IMMUNE SYSTEM DISORDERS NEUROGEN CORP. 2004-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006069-A1 Substituted tetrahydroisoquinolines as C5a receptor modulators C5AR1, C3AR1, C5AR2 C5AR1 1/4885OPRM1 548/4885THRB 497/4885
US-20040204446-A1 Nitrogen compounds such as N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(3-methyl-2-o-tolyl-piperidin-1-yl) -acetamide, administered for prophylaxis arthritis, psoriasis, cardiovascular disorders, reperfusion injury or respiratory system disorders C5AR1, C3AR1, C5AR2 C5AR1 1/4885OPRM1 468/4885THRB 1343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.